The kidney function of a woman with atypical hemolytic uremic syndrome (aHUS) was completely rescued with Soliris (eculizumab), but only after more than a year of treatment, a case study reports. “This case report supports the hypothesis that kidney pathological [disease] resolution in complement-mediated aHUS requires a long…
News
A U.S. woman with atypical hemolytic uremic syndrome (aHUS) has been in disease remission for 13 years while receiving treatment with C5 complement inhibitors after undergoing a kidney transplant, a new report details. According to the researchers, this is the longest reported case in the literature of an aHUS…
Long-term treatment with Ultomiris (ravulizumab) led to sustained clinical improvements for adults and children with atypical hemolytic uremic syndrome (aHUS), according to new two-year data from a pair of clinical trials. Patients in both age groups saw improvements in blood-related health factors and kidney function, and experienced less…
A girl in China had atypical hemolytic uremic syndrome (aHUS) and accompanying protein-losing enteropathy (PLE), a condition in which there is an excessive loss of proteins through the gastrointestinal tract. Treatment with Soliris (eculizumab) resolved both her aHUS-related kidney disease and PLE, according to a report. “Our case…
A toddler developed atypical hemolytic uremic syndrome (aHUS) while receiving chemotherapy to treat cancer, according to a case report. It’s easy for aHUS in cancer patients undergoing chemotherapy to be missed, since its symptoms are often mistakenly assumed to be complications caused by cancer or treatment, said the…
A woman developed atypical hemolytic uremic syndrome (aHUS) after receiving the first dose of a COVID-19 vaccine, according to a case study from Brazil. The researchers said the “connection of symptoms post-COVID-19 vaccination to aHUS … emphasizes the need for ongoing monitoring and research into vaccine-related complications.” The case…
The U.S. Food and Drug Administration (FDA) has approved Epysqli (eculizumab-aagh), a biosimilar to Soliris (eculizumab), as an atypical hemolytic uremic syndrome (aHUS) treatment. Epysqli, from Samsung Bioepis, has also been approved to treat people with paroxysmal nocturnal hemoglobinuria (PNH), a rare disease that, like aHUS,…
The use of Soliris (eculizumab) is changing the natural course of atypical hemolytic uremic syndrome (aHUS) in Latin America as it has in other regions, helping many patients achieve better outcomes, according to a review study. While aHUS arises from the same genetic causes and manifests in a…
A woman in her 60s developed atypical hemolytic uremic syndrome (aHUS) as a result of severe babesiosis, a tick-borne parasitic infection, according to a recent U.S. case report. Babesiosis is caused by a parasite that infects red blood cells. The disease is transmitted from the bite of an infected tick…
Adults with atypical hemolytic uremic syndrome (aHUS) who switched from Soliris (eculizumab) to long-acting Ultomiris (ravulizumab) in a real-world setting experienced no new side effects or worsening of symptoms for up to a year, a study has found. Switching to Ultomiris may be more convenient for patients…
Recent Posts
- How aHUS treatment led to my first tattoos
- Ultomiris at lower doses just as safe, effective for children with aHUS: Study
- Strange symptoms make me wonder if I’m having neurological complications
- Leaky artificial heart valve triggers rare aHUS in woman, 70: Report
- How my body naturally reacts to one of my bad habits
- Study finds alternative pathway is main driver of aHUS
- Rapid, sustained aHUS response seen with Ultomiris in real-world data
- Team care saves mother with trio of postpartum complications
- Once a good side hustle, donating plasma is now too risky for me
- Treatment halts aHUS recurrence after COVID-triggered relapse